Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, January 8, 2014

No link between statins and cognition

I still don't trust statins.
My reasoning, brains are composed of lots of cholesterol, assuming that cholesterol is essential for normal brain function. I don't want to reduce that need for cholesterol.
But don't listen to me, I'm sure your doctor will parrot all the pharma reasons for taking statins.
http://www.clinicaladvisor.com/no-link-between-statins-and-cognition/article/328327/?
A systematic review of available evidence uncovered no association between the use of statins and adverse cognitive outcomes, despite an FDA warning regarding such a relationship.
On February 28, 2012, the FDA announced safety changes to the labeling of statins to warn users that memory loss and confusion had been reported in connection with these agents. The FDA affirmed that these events generally were not serious and disappeared with the discontinuation of statin use. The agency also stated on July 3, 2012, that it continued to believe the cardiovascular benefits of statin therapy outweighed the small increase in cognitive risks.
Noting that despite the FDA warning, the relationship between statins and cognition remained unknown, Karl Richardson, MD, and colleagues undertook an analysis of randomized controlled trials as well as cohort, case-control, and cross-sectional studies evaluating cognition in patients receiving statins.
Low-quality evidence suggested no increased incidence of Alzheimer disease for statin users and no difference in cognitive performance related to procedural memory, attention or motor speed.
Moderate-quality evidence suggested no increased incidence of dementia or mild cognitive impairment, or any change in cognitive performance related to global cognitive performance scores, executive function, declarative memory, processing speed, or visuoperception.
Interestingly, in cohort studies, the risk for dementia was 13% lower among statin users than among nonusers; the risk for Alzheimer disease was 21% lower for statin users; and the risk for mild cognitive impairment was 34% lower for statin users.
Data showed that the reporting rate for cognitive-related adverse events with statins was low and was similar to the rates seen with other commonly prescribed cardiovascular medications.

No comments:

Post a Comment